Press releases

23
Dec 2015
21:30 E.S.T.

Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies

Read more
21
Dec 2015
21:30 E.S.T.

Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 – 14, 2016

Read more
19
Nov 2015
21:30 E.S.T.

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Read more
16
Nov 2015
21:30 E.S.T.

Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results

Read more
5
Nov 2015
21:30 E.S.T.

UCART19: First in Man Proof of Concept to be Presented at 2015 ASH Annual Meeting

Read more
28
Oct 2015
20:30 E.S.T.

Successful GMP Production Process for UCART19

Read more
9
Sep 2015
20:30 E.S.T.

Cellectis Reports Second Quarter and First Half Year 2015 Financial Results

Read more
3
Sep 2015
20:30 E.S.T.

MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy

Read more
27
Aug 2015
20:30 E.S.T.

Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences

Read more
16
Jul 2015
20:30 E.S.T.

Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US